Proscia Stock
| Valuation | $240M1 |
| Valuation Date | Oct 13, 2026 |
| Implied Valuation | $240M |
| Last Price | $3.34 |
| 52-Week High | $3.34 |
| 52-Week Low | $3.34 |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $130M2 |
| Latest Round Amount | n/a |
| Latest Round | Acquired |
| Funding Rounds | 6 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Proscia
Proscia is a software company whose Concentriq platform lets diagnostic laboratories and life sciences groups work from digital tissue images instead of glass slides. Pathologists use it for case review, and scientists use it for biomarker research, clinical trials and companion diagnostics, with optional AI applications on top. Concentriq AP-Dx is cleared by the FDA and CE-IVDR marked for primary diagnosis. The company makes money by selling the platform and related software to labs, health systems and pharmaceutical companies, and by licensing real-world pathology data to biopharma.
News
Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
SANTA CLARA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Proscia®, a provider of digital pathology...
Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
Agilent entered a definitive agreement to acquire Proscia in an all-cash deal valued at $240 million at closing plus up to $30 million in performance milestones. The transaction is expected to close e...
Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
Proscia confirmed Agilent's all-cash acquisition agreement, with CEO David West saying the companies share a vision for open, digital, AI-enabled pathology. Close is expected early in Agilent fiscal 2...
Agilent to buy pathology software maker Proscia for $240 million
Reuters reported Agilent will acquire privately held Proscia for $240 million in cash plus up to $30 million tied to performance targets, expanding Agilent's push into AI-enabled diagnostics. The deal...
Unilabs Advances Digital Pathology Across Europe with Proscia, Shaping the Future of Precision Medicine
Unilabs is deploying Proscia's Concentriq AP-Dx across its European diagnostic network for routine case review, with more countries expected by year-end 2026.
NextGen Pathology Selects Proscia to Establish AI Foundation for Business Growth
Florida-based NextGen Pathology chose Concentriq to add AI to its digital workflows and to support biopharmaceutical research, including Proscia Aperture.
Proscia Earns Top Performance Score in the US, Sweeping 2026 KLAS Digital Pathology Ratings
KLAS Research gave Concentriq the highest US digital pathology performance score (95.2) and named Proscia the most frequently considered vendor among evaluating labs.
Proscia Named Global 2026 Best in KLAS for Digital Pathology in Europe
KLAS awarded Proscia Global 2026 Best in KLAS for Digital Pathology in Europe, with all interviewed customers saying they would buy Concentriq again.
Proscia Unveils Aperture, Making the Moment of Diagnosis the Gateway to Life-Saving Treatments for More Patients
Proscia launched Aperture, which uses AI on routine pathology data from its lab network to surface trial candidates and generate evidence for drug development.
Proscia Cements Leadership in Diagnostic Pathology with 400% Growth in Daily Cases
Proscia said it is on track for 32,000 patients a day to be diagnosed on Concentriq, a 400% year-over-year increase, and launched bundled AI application suites plus 24/7 support.
Fierce Medtech Names AI Pathology Leader Proscia to 2025 Fierce 15
Fierce Medtech named Proscia to its 2025 Fierce 15 list of private healthcare companies. The same week Labcorp said it adopted Concentriq LS for clinical trials and companion diagnostics.
Proscia Raises $50M To Advance AI-Driven Pathology And Deliver The Future Of Precision Medicine
Proscia raised $50 million led by Insight Partners, with AI Capital Partners and Triangle Peak Partners, bringing total funding to $130 million. No post-money valuation was disclosed.
Proscia Launches Concentriq Embeddings and Developer Toolkit to Unleash Pathology AI Development
Proscia launched Concentriq Embeddings to run pathology foundation models inside Concentriq, plus an open-source AI toolkit. A pilot claimed 13x faster algorithm development.
Proscia Receives FDA 510(k) Clearance For Concentriq AP-Dx
The FDA granted 510(k) clearance for Concentriq AP-Dx for primary diagnosis. A multi-site study found digital reads non-inferior to glass slides.
Agilent Announces Global Distribution Agreement with Proscia to Accelerate Data-Driven Precision Medicine
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a multi-year distribution agreement with Proscia® – a leader in digital pathology – to offer a comprehensive d...
Proscia Raises $37M Series C to Fulfill the Promise of Precision Medicine with AI-Enabled Pathology
Proscia raised $37 million in Series C funding from Highline Capital Management, Triangle Peak Partners and Alpha Intelligence Capital, bringing total funding to $72 million.